EMEA-003008-PIP01-21 - paediatric investigation plan

Virus-like particle of SARS-CoV-2 spike protein (recombinant, adjuvant) (CoVLP)
PIPHuman

Key facts

Active Substance
Virus-like particle of SARS-CoV-2 spike protein (recombinant, adjuvant) (CoVLP)
Therapeutic area
Vaccines
Decision number
P/0162/2022
PIP number
EMEA-003008-PIP01-21
Pharmaceutical form(s)
Suspension and emulsion for emulsion for injection
Condition(s) / indication(s)
Prevention of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
Intramuscular use
Contact for public enquiries

Medicago Inc.

Email: atkinsj@medicago.com
Tel. +1 4185694616

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page